JPWO2019196606A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019196606A5 JPWO2019196606A5 JP2021504560A JP2021504560A JPWO2019196606A5 JP WO2019196606 A5 JPWO2019196606 A5 JP WO2019196606A5 JP 2021504560 A JP2021504560 A JP 2021504560A JP 2021504560 A JP2021504560 A JP 2021504560A JP WO2019196606 A5 JPWO2019196606 A5 JP WO2019196606A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- animal
- treatment
- tumor cells
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 claims description 61
- 241001465754 Metazoa Species 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 40
- 238000010171 animal model Methods 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 239000002246 antineoplastic agent Substances 0.000 claims description 22
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 21
- 238000001574 biopsy Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 15
- 239000002609 medium Substances 0.000 claims description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 14
- 229940041181 antineoplastic drug Drugs 0.000 claims description 13
- 239000012510 hollow fiber Substances 0.000 claims description 13
- 102000009016 Cholera Toxin Human genes 0.000 claims description 11
- 108010049048 Cholera Toxin Proteins 0.000 claims description 11
- 229960000643 adenine Drugs 0.000 claims description 11
- 229960000890 hydrocortisone Drugs 0.000 claims description 11
- 229940125396 insulin Drugs 0.000 claims description 11
- 229930024421 Adenine Natural products 0.000 claims description 10
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 10
- 108090001061 Insulin Proteins 0.000 claims description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 8
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 229930182555 Penicillin Natural products 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 239000003797 essential amino acid Substances 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 229940049954 penicillin Drugs 0.000 claims description 7
- 229960005322 streptomycin Drugs 0.000 claims description 7
- 235000020776 essential amino acid Nutrition 0.000 claims description 3
- 230000004565 tumor cell growth Effects 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 57
- 230000000259 anti-tumor effect Effects 0.000 description 35
- 238000011284 combination treatment Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 238000013188 needle biopsy Methods 0.000 description 18
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 16
- 229960004562 carboplatin Drugs 0.000 description 16
- 230000008672 reprogramming Effects 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 230000003833 cell viability Effects 0.000 description 9
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 9
- 229960005277 gemcitabine Drugs 0.000 description 9
- 229960001592 paclitaxel Drugs 0.000 description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
- 230000010304 tumor cell viability Effects 0.000 description 9
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 9
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 8
- 101800003838 Epidermal growth factor Proteins 0.000 description 8
- 229960004316 cisplatin Drugs 0.000 description 8
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 8
- 229940116977 epidermal growth factor Drugs 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000002033 PVDF binder Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 229960001756 oxaliplatin Drugs 0.000 description 7
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 7
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 6
- 229960004768 irinotecan Drugs 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229960003668 docetaxel Drugs 0.000 description 5
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 229960005079 pemetrexed Drugs 0.000 description 4
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019049 Hair texture abnormal Diseases 0.000 description 2
- 208000015850 Malignant peritoneal mesothelioma Diseases 0.000 description 2
- 238000011794 NU/NU nude mouse Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- -1 transplantation Substances 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101100518728 Homo sapiens PALB2 gene Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101150099884 PALB2 gene Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2018/083110 | 2018-04-13 | ||
CN2018083110 | 2018-04-13 | ||
PCT/CN2019/078703 WO2019196606A1 (en) | 2018-04-13 | 2019-03-19 | Method for obtaining an animal model from conditionally reprogrammed cells and use of the animal model for screening anti-tumor drugs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021520848A JP2021520848A (ja) | 2021-08-26 |
JPWO2019196606A5 true JPWO2019196606A5 (zh) | 2022-03-29 |
JP7478720B2 JP7478720B2 (ja) | 2024-05-07 |
Family
ID=68163925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021504560A Active JP7478720B2 (ja) | 2018-04-13 | 2019-03-19 | 条件付き再プログラム化細胞から動物モデルを得るための方法および抗腫瘍薬のスクリーニングのための動物モデルの使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20210047622A1 (zh) |
EP (1) | EP3775170A4 (zh) |
JP (1) | JP7478720B2 (zh) |
KR (1) | KR20210005073A (zh) |
CN (1) | CN112334575A (zh) |
AU (1) | AU2019250859A1 (zh) |
CA (1) | CA3096561A1 (zh) |
SG (1) | SG11202010129WA (zh) |
WO (1) | WO2019196606A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107976534A (zh) * | 2016-10-21 | 2018-05-01 | 上海立迪生物技术股份有限公司 | 一种抗肿瘤药物快速药效筛选方法及其专用装置 |
CN113249325B (zh) * | 2020-02-11 | 2023-02-17 | 合肥中科普瑞昇生物医药科技有限公司 | 食管鳞癌原代细胞的培养基及培养方法 |
CN113403278B (zh) * | 2020-03-16 | 2023-02-17 | 合肥中科普瑞昇生物医药科技有限公司 | 胃癌原代细胞的培养基及培养方法 |
JP7464977B2 (ja) | 2020-06-10 | 2024-04-10 | 国立大学法人東京農工大学 | イヌ中皮腫細胞株 |
CN115029316B (zh) * | 2022-06-20 | 2024-04-30 | 华中科技大学同济医学院附属协和医院 | 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用 |
CN117660581A (zh) * | 2022-09-01 | 2024-03-08 | 上海立迪生物技术股份有限公司 | 一种筛选免疫调节药物药效的模型及方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3252361B2 (ja) * | 1991-10-02 | 2002-02-04 | ミルトン・エイチ・リプスキー | インビボにおける癌の治療のアッセイ |
CA2486548A1 (en) * | 2002-05-30 | 2003-12-11 | Raven Biotechnologies, Inc. | Animal model for toxicology and dose prediction |
KR20100005116A (ko) * | 2007-04-27 | 2010-01-13 | 주식회사 이매진 | 면역 조절제 스크리닝 방법 |
CA2817712C (en) | 2010-11-12 | 2020-03-24 | Georgetown University | Immortalization of epithelial cells and methods of use |
KR101327533B1 (ko) * | 2012-12-11 | 2013-11-08 | 사회복지법인 삼성생명공익재단 | 환자 맞춤형 항암제 선별용 시스템 |
SG11201507510PA (en) | 2013-03-15 | 2015-10-29 | Jackson Lab | Isolation of non-embryonic stem cells and uses thereof |
CN103898056B (zh) * | 2014-03-11 | 2016-09-07 | 山东大学附属千佛山医院 | 细胞培养基及其在培养人原代肿瘤细胞中的应用 |
CN107541494B (zh) * | 2016-06-27 | 2022-11-29 | 上海市东方医院 | 一种人胆管癌细胞系及其应用 |
CN107541496A (zh) * | 2016-06-27 | 2018-01-05 | 安徽省立医院 | 一种人食管癌细胞系及其应用 |
-
2019
- 2019-03-19 CN CN201980039991.5A patent/CN112334575A/zh active Pending
- 2019-03-19 CA CA3096561A patent/CA3096561A1/en active Pending
- 2019-03-19 EP EP19784485.5A patent/EP3775170A4/en active Pending
- 2019-03-19 AU AU2019250859A patent/AU2019250859A1/en active Pending
- 2019-03-19 SG SG11202010129WA patent/SG11202010129WA/en unknown
- 2019-03-19 KR KR1020207032894A patent/KR20210005073A/ko unknown
- 2019-03-19 WO PCT/CN2019/078703 patent/WO2019196606A1/en active Application Filing
- 2019-03-19 JP JP2021504560A patent/JP7478720B2/ja active Active
- 2019-03-19 US US17/046,981 patent/US20210047622A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7478720B2 (ja) | 条件付き再プログラム化細胞から動物モデルを得るための方法および抗腫瘍薬のスクリーニングのための動物モデルの使用 | |
CN108148811B (zh) | 一种基于温敏型生物凝胶三维培养体系建立结直肠癌患者来源的异种移植瘤模型的方法 | |
KR20160033180A (ko) | 생물학적 조직에 혈관계를 부여하는 방법 | |
Bersini et al. | Tackling muscle fibrosis: from molecular mechanisms to next generation engineered models to predict drug delivery | |
CN1325271A (zh) | 能快速生长并产生增殖抑制性物质的受限细胞的组合物及其用途 | |
CN101827933A (zh) | 治疗肾功能衰竭的选择性细胞疗法 | |
WO2011068183A1 (ja) | 癌細胞凝集塊およびその調製法 | |
CN106102753A (zh) | 治疗赘生物形成的方法 | |
Xiang et al. | Direct in vivo application of induced pluripotent stem cells is feasible and can be safe | |
CN114181903A (zh) | 结直肠癌类器官培养基及无支架3d培养方法 | |
CN109182271A (zh) | 基于类器官方法构建正常免疫小鼠人胃癌移植瘤模型的方法和应用 | |
CN106754719B (zh) | 一种接种液组合物及利用其构建恶性胸腔积液来源异种移植瘤动物模型的方法 | |
CN114717190A (zh) | 一种人乳腺恶性叶状肿瘤细胞系bpt0713及其应用 | |
CN110511901A (zh) | 生物人工近端小管系统及使用方法 | |
CN109152799A (zh) | 胰腺干细胞及其用途 | |
JPWO2019196606A5 (zh) | ||
JP5809782B2 (ja) | 癌組織由来細胞塊または癌細胞凝集塊の薬剤または放射線感受性評価方法 | |
Sun et al. | Isolation of ready-made rat microvessels and its applications in effective in vivo vascularization and in angiogenic studies in vitro | |
CN101003792A (zh) | 稳定表达萤火虫荧光素酶的9lluc细胞株的构建与应用 | |
CN113943755A (zh) | 构建原位原发食管癌动物模型的方法 | |
CN104755610B (zh) | 脂肪组织细胞 | |
KR102475776B1 (ko) | 암 오가노이드 및 내피 집락 세포를 이용한 대장암 이종이식 동물 모델 및 그 제조방법 | |
CN107460170B (zh) | 人垂体腺瘤细胞系的建立及其应用 | |
JP7197203B2 (ja) | ヒト血管の形成、構造または機能に影響を及ぼす物質のスクリーニング方法、およびヒト血管の製造方法 | |
CN112266960A (zh) | 一种Msi1在制备用于治疗胃癌制剂及预测化疗药物耐受中的应用 |